[HTML][HTML] Oral selinexor–dexamethasone for triple-class refractory multiple myeloma
…, H Chang, S Parekh, Y Landesman… - … England Journal of …, 2019 - Mass Medical Soc
Background Selinexor, a selective inhibitor of nuclear export compound that blocks exportin
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, …
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, …
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
…, JR Saint-Martin, H Chang, Y Landesman… - The Lancet …, 2020 - thelancet.com
Background Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive
cancer with a median overall survival of less than 6 months. We aimed to assess the …
cancer with a median overall survival of less than 6 months. We aimed to assess the …
First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors
…, JR Saint-Martin, R Carlson, Y Landesman… - Journal of Clinical …, 2016 - ascopubs.org
Purpose This trial evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy
of selinexor (KPT-330), a novel, oral small-molecule inhibitor of exportin 1 (XPO1/CRM1), …
of selinexor (KPT-330), a novel, oral small-molecule inhibitor of exportin 1 (XPO1/CRM1), …
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
…, JE Neggers, S Mendiratta, S Wei, Y Landesman… - Nature, 2016 - nature.com
The common participation of oncogenic KRAS proteins in many of the most lethal human
cancers, together with the ease of detecting somatic KRAS mutant alleles in patient samples, …
cancers, together with the ease of detecting somatic KRAS mutant alleles in patient samples, …
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias
…, G Ferenchak, JJ Ellis, Y Landesman… - Blood, The Journal …, 2013 - ashpublications.org
As tyrosine kinase inhibitors (TKIs) fail to induce long-term response in blast crisis chronic
myelogenous leukemia (CML-BC) and Philadelphia chromosome–positive (Ph + ) acute …
myelogenous leukemia (CML-BC) and Philadelphia chromosome–positive (Ph + ) acute …
[PDF][PDF] Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing
…, E Baloglu, S Shacham, M Crochiere, Y Landesman… - Chemistry & biology, 2015 - cell.com
Validation of drug-target interaction is essential in drug discovery and development. The
ultimate proof for drug-target validation requires the introduction of mutations that confer …
ultimate proof for drug-target validation requires the introduction of mutations that confer …
Clinical translation of nuclear export inhibitors in cancer
WT Senapedis, E Baloglu, Y Landesman - Seminars in cancer biology, 2014 - Elsevier
Clinical targeting of multi-dimensional proteins such as the proteasome has been efficacious
in recent years. Inhibitors such as bortezomib and carfilzomib have been used successfully …
in recent years. Inhibitors such as bortezomib and carfilzomib have been used successfully …
[HTML][HTML] Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to …
…, M Lee, M Kauffman, S Shacham, Y Landesman - Oncotarget, 2016 - ncbi.nlm.nih.gov
The nuclear export protein, exportin-1 (XPO1/CRM1), is overexpressed in many cancers
and correlates with poor prognosis. Selinexor, a first-in-class Selective Inhibitor of Nuclear …
and correlates with poor prognosis. Selinexor, a first-in-class Selective Inhibitor of Nuclear …
Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B‐cell …
…, C Haioun, C Argueta, Y Landesman… - American journal of …, 2016 - Wiley Online Library
Primary mediastinal B‐cell lymphoma (PMBL) is an entity of B‐cell lymphoma distinct from
the other molecular subtypes of diffuse large B‐cell lymphoma (DLBCL). We investigated the …
the other molecular subtypes of diffuse large B‐cell lymphoma (DLBCL). We investigated the …
[HTML][HTML] KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
…, RM Stone, E Baloglu, W Senapedis, Y Landesman… - Leukemia, 2017 - nature.com
Acute myeloid leukemia (AML) is a clonal hematologic malignant disease of developing
myeloid cells that have acquired aberrant survival, uncontrolled proliferation and a block in …
myeloid cells that have acquired aberrant survival, uncontrolled proliferation and a block in …
